Feb 5, 2025 · Invivyd creates medicines that are more potent and resistant to virus evolution than the human immune system. We deploy a proprietary integrated technology platform unique in the industry to assess, monitor, develop, and adapt to create best in class antibodies.

Feb 3, 2025 · About Invivyd Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies.

Invivyd is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases.

With our INVYMAB™ platform approach, we aim to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats.

WALTHAM, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced the submission to the U.S. Food and Drug Administration (FDA) of an updated immunobridging analysis of pemivibart as ongoing support of a potential ...

Dec 18, 2023 · Invivyd is evaluating the 4500 mg dose of VYD222 in the CANOPY clinical trial. About VYD222 VYD222 is a broadly neutralizing, half-life extended monoclonal antibody (mAb) candidate in development for the prevention of symptomatic COVID-19 in vulnerable populations, such as immunocompromised people.

Feb 3, 2025 · Invivyd previously guided expectations to finish 2024 with $65 million or more in cash and cash equivalents and targeted near-term (by end of 1H 2025) profitability with existing cash and cash ...

Jun 26, 2023 · Invivyd and the FDA have agreed on a path toward potential emergency use authorization of the biotech’s lead monoclonal antibody (mAb) and possible follow-on candidates designed to prevent...

WALTHAM, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today...

Feb 3, 2025 · Invivyd expects to present further data from the trial, including efficacy and long-term pharmacokinetics this quarter. IVVD closed Friday's (Jan.31 2025) trading at $0.35 down by 8.28%. In ...